Dexcom CGM:  Technology Updates and The Broad Ecosystem of Partner AID Systems - Industry Symposium Supported by Dexcom

BAQSIMI and Diabetes Technology: Where Do They Fit into Total Patient Care? - Industry Symposium Supported by Eli Lilly

Session description -Welcome to BAQSIMI® (glucagon) nasal powder 3mg and Diabetes Technology: Where Do They Fit Into Total Patient Care? presented by Tadej Battelino, MD, PhD, and Marga Giménez, MD, PhD. During this symposium presentation, we will discuss how diabetes technology, hypoglycaemia, and BAQSIMI are connected within total patient care. We will share information about BAQSIMI - the first and only glucagon with nasal administration - including product attributes, clinical data, and product use and administration. In addition, we will highlight the importance of preparing people with diabetes, and those around them, for severe hypoglycaemia rescue—just in case. Thank you for joining us!

The materials for Baqsimi® (glucagon) nasal powder 3mg contained in this virtual symposium are approved following the Summary of Product Characteristics (SPC). Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

The Journey of Omnipod®: From Improved Clinical Outcomes to Shaping the Future of Novel Integrated Tubeless Technology. - Industry Symposium Supported by Insulet

Session description - Objective: The Insulet Sponsored Symposium will explore how the simplicity of the Omnipod DASH® Insulin Management System is benefiting various patient groups, supported by a review of the latest real-world evidence and practical patient case studies. The discussion will expand into how Omnipod® is shaping the future of novel tubeless automated insulin delivery technology with Omnipod® 5.

Introducing Tempo: A Connected Insulin Pen to Simplify Diabetes Management - Industry Symposium Supported by Eli Lilly

Session description - This symposium will introduce Tempo™, a Personalized Diabetes Management System from Eli Lilly, that integrates insulin dosing data with technology to help simplify diabetes management.   Digital health technologies can help improve patient data visibility, physician-patient collaboration, clinical decision-making, and patient self-management, ultimately leading to better outcomes.   Faculty will discuss the complexities of insulin management, and how insulin dosing data may help facilitate communication between you and the people you treat.  Automating insulin dosing data may help:  

• Gain an understanding of their management patterns

• Stay informed between office visits

• Feel empowered to engage in shared decision-making

The Tempo Smart Button™ (pending CE mark) attaches to a Tempo Pen™ prefilled with Abasaglar, Humalog, or Lyumjev insulin.  Data from the Tempo System will integrate with commercially available software. The Tempo Smart Button is intended to reliably store and transmit insulin dosing data to a compatible app.  Tempo provides a comprehensive view of how people manage their insulin day-to-day.  Adding insulin dosing data to other data related to your patients’ insulin therapy (e.g., blood glucose, carbohydrate intake) may help inform treatment decisions. This program is for all healthcare professionals treating people with diabetes on multiple daily injections of mealtime insulin.

The materials for Tempo Pen™ contained in this virtual symposium are approved for use only in EU and UK. The Tempo Smart Button™ is pending CE mark. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Chronic kidney disease and diabetes: New renal and cardiovascular outcomes - Industry Symposium Supported by Sciarc GmbH

Session description - People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone. The symposium will address unmet needs in the treatment of diabetic kidney disease and presents strategies to reduce the burden. New data on kidney failure and disease progression of chronic kidney disease will be presented. Outcomes of the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes will be highlighted. In the study, finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease. Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progression. The symposium will also focus on the clinical and practical aspects of mineralocorticoid antagonists in chronic kidney disease and type 2 diabetes.

Breaking the Glass Ceiling on Traditional Use of rtCGM: New Trends and Evidence in rtCGM - Industry Symposium Supported by Dexcom